A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors.

Isabel Fernández-Pisonero, Laura Clavaín, Javier Robles-Valero, L Francisco Lorenzo-Martín, Rubén Caloto, Blanca Nieto, Carmen García-Macías, Clara L Oeste, Manuel Sánchez-Martín, Antonio Abad, Alejandro Hortal, Dolores Caballero, Marcos González, Mercedes Dosil, Balbino Alarcón

March 2022 Cell Rep

Synopsis of Social media discussions

The discussions strongly support the publication’s findings, with posts describing the RRAS2 mutation as a 'potent oncogenic driver' and discussing its implications for therapy, indicating high agreement and perceived impact. The tone is enthusiastic, with words like 'advance' and 'potent,' and examples include mentions of how this discovery opens new treatment avenues, reflecting deep engagement and recognition of the research's significance.

A
Agreement
 Strong agreement

Most discussions express strong approval, highlighting the significance of the findings and their potential impact on cancer research.

I
Interest
 High level of interest

Posts show high curiosity and enthusiasm, often referencing exciting breakthroughs and advances in understanding tumor drivers.

E
Engagement
 Moderate level of engagement

Many comments reference detailed aspects such as the mutation’s role and therapeutic potential, indicating active and thoughtful engagement.

I
Impact
 High level of impact

The discussions consistently emphasize the importance of the research, suggesting it could influence future cancer therapies and understanding of oncogenic processes.

Social Mentions

YouTube

4 Videos

Twitter

25 Posts

News

4 Articles

Metrics

Video Views

3,306

Total Likes

75

Extended Reach

239,652

Social Features

33

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

New Oncogenic Gene RRAS2 and Its Therapeutic Vulnerabilities

New Oncogenic Gene RRAS2 and Its Therapeutic Vulnerabilities

This video summarizes a scientific article published by Xos Bustelo's team in Cell Reports, March 2022, identifying the RRAS2 gene mutation that promotes various cancers and exploring its mechanisms and potential treatments, with implications for other diseases like Noonan syndrome.

Centro de Investigación del Cáncer_ USAL-CSIC

May 27, 2022

2,523 views

RRAS2 Mutation as a Potent Oncogenic Driver in Various Tumors

RRAS2 Mutation as a Potent Oncogenic Driver in Various Tumors

A mutation in the RRAS2 gene acts as a strong oncogenic driver across multiple tumor types. Recent research using a mouse model shows RRAS2 causes rapid tumor formation, primarily relying on the mTORC1 pathway for growth, offering potential therapeutic targets.

Pix Videos Production Company

June 3, 2022

509 views

RRAS2 Mutation as a Broad-Oncogenic Driver in Tumors

RRAS2 Mutation as a Broad-Oncogenic Driver in Tumors

A mutation in the RRAS2 gene acts as a potent oncogenic driver across various tumor types by promoting rapid tumor formation, primarily through the mTORC1 pathway. These tumors show unique responses to targeted therapies, offering potential treatment avenues.

Xosé Bustelo

May 26, 2022

147 views

RRAS2 Mutation as a Potent Oncogenic Driver in Tumors

RRAS2 Mutation as a Potent Oncogenic Driver in Tumors

This video summarizes a study published in Cell Reports revealing how mutations in the RRAS2 gene promote various cancers. Using a mouse model, the research shows RRAS2-driven tumors rely on the mTORC1 pathway, highlighting potential targeted therapies.

Xosé Bustelo

May 26, 2022

128 views

  • Biosíntesis podcast
    @bio_sintesis (Twitter)

    RT @XRBustelo:
    view full post

    July 17, 2022

    7

  • Xose R Bustelo
    @XRBustelo (Twitter)

    RT @XRBustelo:
    view full post

    July 15, 2022

    7

  • Xose R Bustelo
    @XRBustelo (Twitter)

    RT @XRBustelo:
    view full post

    July 15, 2022

    8

  • Revista SEBBM
    @SEBBM_Revista (Twitter)

    En @SEBBM_Revista n°212 -junio | Una mutación de RRAS2 actúa como potente inductor oncogénico | Fernández-Pisonero et al. @usal https://t.co/ApSRW6MxL3
    view full post

    July 7, 2022

  • Pablo Hortal
    @PixVideos_ (Twitter)

    Identification of R-RAS2 as a new oncogenic driver https://t.co/4JjnogNvfV
    view full post

    June 4, 2022

  • Xose R Bustelo
    @XRBustelo (Twitter)

    RT @XRBustelo:
    view full post

    May 28, 2022

    7

  • Xose R Bustelo
    @XRBustelo (Twitter)

    RT @XRBustelo:
    view full post

    May 28, 2022

    8

  • Xose R Bustelo
    @XRBustelo (Twitter)

    RT @CICancer_com: Compartimos el vídeo que explica el avance del laboratorio de @XRBustelo que difundimos en https://t.co/T9iqZozLRd que es…
    view full post

    May 27, 2022

    1

  • Centro de Investigación del Cáncer/CSIC-USAL-FICUS
    @ciccancer (Twitter)

    Compartimos el vídeo que explica el avance del laboratorio de @XRBustelo que difundimos en https://t.co/T9iqZozLRd que está disponible en nuestro canal de YouTube https://t.co/ZqtLfH3Odr
    view full post

    May 27, 2022

    1

    1

  • BruzosAliciaL, Dr. (she/her)
    @BruzosAliciaL (Twitter)

    RT @XRBustelo:
    view full post

    May 27, 2022

    7

  • Toni Celia-Terrassa
    @TCeliaTerrassa (Twitter)

    RT @XRBustelo:
    view full post

    May 26, 2022

    7

  • Laura Quevedo
    @lauriquepa (Twitter)

    RT @XRBustelo:
    view full post

    May 26, 2022

    8

  • Juan Rodriguez Vita
    @J_RodriguezVita (Twitter)

    RT @XRBustelo:
    view full post

    May 26, 2022

    8

  • Luis Paz-Ares
    @LuisPaz_Ares (Twitter)

    RT @XRBustelo:
    view full post

    May 26, 2022

    8

  • Marisol Soengas
    @msmelanoma (Twitter)

    RT @XRBustelo:
    view full post

    May 26, 2022

    7

  • Grupo R Comunicación
    @GrupoRComunica (Twitter)

    RT @XRBustelo:
    view full post

    May 26, 2022

    8

  • RamonReyes
    @RamonReyesCC (Twitter)

    RT @XRBustelo:
    view full post

    May 26, 2022

    7

  • Javier Robles
    @JaviRoblesV (Twitter)

    RT @XRBustelo:
    view full post

    May 26, 2022

    8

  • Conexión Cáncer CSIC
    @CancerCSIC (Twitter)

    RT @XRBustelo:
    view full post

    May 26, 2022

    8

  • Xose R Bustelo
    @XRBustelo (Twitter)


    view full post

    May 26, 2022

    17

    7

  • Xose R Bustelo
    @XRBustelo (Twitter)


    view full post

    May 26, 2022

    36

    8

  • QiDa
    @fast04050146 (Twitter)

    RT @CellReports: A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors https://t.co…
    view full post

    March 17, 2022

    2

  • Victoria Hendry
    @HendryVictoria (Twitter)

    RT @CellReports: A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors https://t.co…
    view full post

    March 17, 2022

    2

  • Cell Reports
    @CellReports (Twitter)

    A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors https://t.co/DGGCSBaj6r
    view full post

    March 17, 2022

    7

    2

  • Xose R Bustelo
    @XRBustelo (Twitter)

    ❓Do you want to see the actual data ? If so, use this link
    view full post

    March 16, 2022

    4

Abstract Synopsis

  • A mutation in the RRAS2 gene, similar to known cancer-driving mutations in RAS proteins, acts as a strong oncogenic driver across various tumor types, but its specific role in tumor development in living organisms was previously unclear.
  • Using a mouse model with an inducible RRAS2 mutation, researchers found that RRAS2 causes rapid tumor formation, which differs from tumors caused by classical RAS genes, and these tumors can be grouped based on their response to treatments.
  • The study reveals that tumors driven by RRAS2 rely heavily on the mTORC1 pathway for growth, making it a promising target for therapy, especially since these tumors are independent of other common signaling pathways like PI3K, MEK, and Ral.]